Study: Hidden Conflicts of Interest Permeate Medicine

Three investigations reveal the influence of industry money in patient advocacy groups, treatment guidelines, and Twitter feeds.

Written byDiana Kwon
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

PIXABAY The pharmaceutical industry’s influence extends to as patient advocacy groups, Twitter feeds, and guidelines submitted to federal agencies, according to a series of studies published January 17 in JAMA Internal Medicine. Susannah Rose of the Office of Patient Experience at the Cleveland Clinic surveyed roughly 300 patient advocacy groups and found that 67 percent of these groups received money from for-profit companies in the past year. Among the groups that got industry money, 12 percent received more than half their funding from industry.

“The question here is: 'Is the organization working for the money? Or, is it really working for the best interests of the people it's supposed to serve?” Rose told MedPage Today. She added these groups may be tempted to endorse expensive drugs that do not necessarily benefit the people they serve, and may even engage in “cause marketing,” which is when patient organizations are paid to give a “seal of approval” to a product.

Another group, led by G. Caleb Alexander of Johns Hopkins, found that industry-backed organizations were less supportive of the guidelines for opioid prescriptions released by the Centers for Disease Control last year. The group investigated comments from 158 organizations and found that within the 20 percent of negative critics, many were ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Diana is a freelance science journalist who covers the life sciences, health, and academic life. She’s a regular contributor to The Scientist and her work has appeared in several other publications, including Scientific American, Knowable, and Quanta. Diana was a former intern at The Scientist and she holds a master’s degree in neuroscience from McGill University. She’s currently based in Berlin, Germany.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies